BriaCell Therapeutics has successfully priced a best-efforts public offering of 5,366,726 units, generating gross proceeds of approximately $30 million before placement agent fees and expenses. Each unit includes a common share or pre-funded warrant and a warrant exercisable into one share, with the warrants approved for listing on the Nasdaq Capital Market under the symbol BCTXL, expected to begin trading on January 14, 2026. The offering is scheduled to close on January 15, 2026, subject to customary conditions. BriaCell intends to deploy net proceeds to fund working capital, corporate purposes and advancement of its immunotherapy pipeline. ThinkEquity acted as sole placement agent for the transaction.

In the Phase 1/2a Bria-OTS study, a 78-year-old woman with hormone receptor-positive, HER2-negative metastatic breast cancer achieved a sustained complete resolution of a lung metastasis after four doses of Bria-OTS monotherapy. This 100% response was first observed at two months and confirmed at four, six and now eleven months, with no treatment-limiting toxicities reported. The patient completed 17 cycles of therapy and continues in survival follow-up. The dose escalation phase of the study is complete, and the Phase 2a cohort combining Bria-OTS with an immune checkpoint inhibitor is now underway.